BRUNSWICK, Maine — Maridose, a DEA-licensed manufacturer specializing in cannabis-based products, launched its Contract Research Organization (CRO) group. This newly formed group is dedicated to collaborating with researchers engaged in the development of cannabis-based drugs for pre-clinical and clinical trials, as well as aiding in the commercialization process.
Recognizing the burgeoning opportunities and the critical need for advanced research in the field of cannabis-based medicine, Maridose is positioned to facilitate breakthroughs in the pharmaceutical and biotech sectors. The company’s innovative CRO services cater to pharmaceutical and biotech firms, academic institutions, authorized cannabis companies, and other entities legally permitted to conduct research on Schedule I drugs.
Maridose’s CRO services encompass a comprehensive suite of offerings designed to support every phase of drug development, from initial research to final commercialization.
Maridose’s CEO Lisa Rich-Milan said, “As the only DEA-licensed manufacturer providing comprehensive CRO services, the launch of our CRO group marks a significant milestone for the research community. We are dedicated to fostering advancements in cannabis-based medicine and are committed to supporting researchers and organizations striving to make breakthroughs in this rapidly evolving field.”
About Maridose
Maridose is a leading DEA-licensed biopharmaceutical research and product development company focused on cannabis and cannabis-derived products. The company was selected by the U.S. Department of Justice and Drug Enforcement Agency to legally cultivate, manufacture and sell cannabis and cannabis-derived products under federal law for research and pharmaceutical applications. Maridose’s Center of Excellance is located in Brunswick Landing, Maine providing best-in-class cannabis cultivation, research and product development.
